CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01253070
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:33.184769+00:00
Published At: 2016-02-11T00:00:00+00:00
Record Updated At: 2022-08-04
Results Posted At: 2016-02-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Myeloid Leukemia With FLT3/ITD Mutation", "Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11", "Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Acute Promyelocytic Leukemia With PML-RARA", "FLT3 Gene Mutation", "Therapy-Related Acute Myeloid Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-08-04"
protocolSection.identificationModule.nctId: "NCT01253070"
protocolSection.identificationModule.officialTitle: "A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients \u0026gt;/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2016-02-11"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.